CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes, CDR-SB, or any of its key secondary endpoints – change from baseline in Timed Up and Go, TUG, test, change from baseline in a Neuropsychological Test Battery, NTD, and the Clinician’s Global Impression of Change, CGIC. Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.